EREBRAL vasospasm after subarachnoid hemorrhage (SAH) is a major clinical problem in the field of neurosurgery. Although intensive efforts have been made to investigate the pathogenesis of this phenomenon, the issue remains unresolved. Therefore, a therapeutic approach for preventing vasospasm has not been established. Considerable evidence has implicated hemoglobin and other erythrocyte constituents in the pathogenesis of vasospasm after SAH. One of the consequences of SAH is exposure of the cerebral vessels to direct contact with blood and/or oxyhemoglobin.
EREBRAL vasospasm after subarachnoid hemorrhage (SAH) is a major clinical problem in the field of neurosurgery. Although intensive efforts have been made to investigate the pathogenesis of this phenomenon, the issue remains unresolved. Therefore, a therapeutic approach for preventing vasospasm has not been established. Considerable evidence has implicated hemoglobin and other erythrocyte constituents in the pathogenesis of vasospasm after SAH. One of the consequences of SAH is exposure of the cerebral vessels to direct contact with blood and/or oxyhemoglobin. 2, 17 Oxyhemoglobin stimulates the synthesis of endothelin-1 (ET-1), which is an extremely potent and long-lasting cerebral vasoconstrictor. 6, 22 Hence, it has been hypothesized that ET-1 plays an important role in the pathogenesis of cerebral vasospasm after SAH. The induction of ET-1 is considered to be regulated at the messenger (m)RNA transcription level. 33 Based on these findings, we used antisense oligoDNA for preproendothelin-1 (ppET-1) mRNA to prevent cerebral vasospasm after SAH in rats.
A recent report demonstrated that the ET-1 gene was disrupted in mouse embryonic stem cells by homologous recombination to create mice deficient in ET-1.
14 Although there is a possibility that ET-1 may be involved in the pathogenesis of hemolysate-induced vasoconstriction, the phenotype of the ET-1-deficient mice presented abnormal manifestations in fetal development and hemodynamics, which, intriguingly, indicates that ET-1 plays an important direct biological role in mouse development.
To inhibit the hemolysate-induced vasoconstriction we administered antisense oligoDNA for ppET-1 mRNA. Antisense oligoDNA is often efficient for analyzing gene function in vitro, and is considered to bind specifically to the targeted complementary sequences at the level of transcription, RNA processing, translocation, or translation, thereby reducing the specific gene expression. 30 Recently antisense oligoDNA was used to regulate gene expression in an in vivo vascular system; antisense oligo-DNA for the c-myb gene was introduced in a ballooninjured rat carotid artery by adventitial application, and the results indicated that it could suppress the proliferation and migration of smooth-muscle cells. 26 In the same model, data indicated that antisense oligoDNA for cdc2 kinase and proliferating cell nuclear antigen mRNAs, delivered by intraluminal application, suppressed neointimal hyperplasia. 19 In the present investigation, we introduced antisense oligoDNA complementary to mRNA for ppET-1 in a rat vasospasm model to clarify the role of ET-1 in the etiology of hemolysate-induced vasoconstriction. Our results suggest that this antisense approach might be useful for preventing cerebral vasospasm after SAH.
Inhibition of vascular contraction by intracisternal administration of preproendothelin-1 mRNA antisense oligoDNA in a rat experimental vasospasm model
Materials and Methods

OligoDNA Production
The sequences for the oligoDNAs used in this study were 5Ј-ATCACGGGAAAATAATCCAT-3Ј(antisense strand oligoDNA) and 5Ј-ATGGATTATTTTCCCGTGAT-3Ј(sense strand oligo-DNA), which included an initiation codon. The oligoDNAs were prepared with phosphorothioate modification because they are more stable in cerebrospinal fluid (CSF) than those with phosphodiesters. 31 The oligoDNAs were diluted in Tris-ethylenediamine tetraacetic acid (EDTA) buffer to a concentration of 100 M. Because the total volume of CSF in the rat is approximately 1 ml, 100 l of the 100 M of phosphorothioate oligoDNA was diluted to a 10-M concentration, which does not show apparent cytotoxicity (see Results). The sequence similarities were checked against the reported DNA sequences present in the Genebank/European Molecular Biology Lab database, and we could find no sequences significantly related to them.
Cytotoxicity Assays
Cytotoxicity of the phosphorothioate oligoDNA was assayed by the microculture tetrazolium method. 20 The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) was dissolved in phosphate-buffered saline (PBS) at 5 mg/ml. Human lung fibroblasts (MRC-9) were subcultured 33 to 35 times and seeded at 10 4 cells/300 l medium in each well of a 96-well microtiter plate, and cultured at 37˚C for 48 hours. Eagle's minimum essential medium containing 10% fetal calf serum was used to maintain cultures. The medium was aspirated, and 80 l of medium and each of various concentrations of phosphorothioate oligoDNA dissolved in 20 l of Tris-EDTA were added to each well. After 24 hours of incubation, 20 l of MTT solution (5 mg of tetrazolium/ml in PBS) was added to each well. After an additional 4 hours, the culture medium was aspirated, and 150 l of 0.04 N HCl/isopropyl alcohol was added to each well. The plates were then shaken vigorously to dissolve the formazan, and the absorbance at 570 nm for samples and 630 nm for the references was measured with a microplate spectrophotometer.
Hemolysate Preparation
The arterial blood collected from a rat was centrifuged at 2500 G for 15 minutes, and the supernatant was discarded. The erythrocyte fraction was washed three times with saline (volume of saline/ erythrocyte fraction ratio, 1:3). After the erythrocytes had been disintegrated by ultrasonic waves, the particulate material was centrifuged at 15,000 G for 90 minutes, and the supernatant (hemolysate) was collected. The oxyhemoglobin concentration was measured by the cyanomethemoglobin method.
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In several preliminary experiments we confirmed that the vasoconstrictive effect of hemolysate on cerebral arteries was proportional to the concentration of oxyhemoglobin in the hemolysate. Because the maximum constriction level was reached at the concentration of 10 Ϫ5 M oxyhemoglobin, 24, 27 in the following studies we used hemolysate containing 10 Ϫ3 M oxyhemoglobin to examine the strong inhibitory effect of antisense drugs on the vascular system. We adjusted the hemolysate to an oxyhemoglobin concentration of 10 Ϫ3 M by diluting with saline.
Surgical Protocol
Intracisternal Injection of OligoDNAs. Male Sprague-Dawley rats were used in this study. We modified the previously reported method developed by Kubota, et al., 13 for the present investigation. Briefly, after the induction of general anesthesia with 30 mg/kg of pentobarbital administered intraperitoneally, the scalp was incised, and a small hole was made in the midline just rostral to the interparietal-occipital suture. The occipital bone and the atlantooccipital membrane were then exposed. A cannula was passed through the hole and advanced into the cisterna magna by sliding it along the inner table of the occipital bone. The cannula was then fixed with bone wax. Ten nanomoles of oligoDNAs diluted with 100 l of Tris-EDTA or Tris-EDTA only was injected into the cisterna magna through the cannula.
Cervical Transclival Approach. After induction of general anesthesia in the rats with 30 mg/kg of pentobarbital injected intraperitoneally, intubation by tracheotomy and ventilation was performed, and a skin incision was made along the midline in the neck. The cervical musculature and carotid artery were gently retracted, and the clivus was exposed and viewed with the aid of an operating microscope. A window 3 mm in diameter was drilled in the midline, and the dura mater and arachnoid membrane were carefully removed to expose the basilar artery (BA). 3 The animals were handled in a humane fashion that met the public health standards at Okayama University Medical School.
Fluorescence Microscopy
To confirm whether antisense oligoDNA directly injected into the cisterna magna is incorporated into the basilar arterial wall, we used fluorescence to trace the antisense oligoDNA. Therefore, 100 l of fluorescein-labeled antisense oligoDNAs was injected via the cisterna magna. Twenty-four hours later, the BA together with the brainstem were perfused, then rapidly removed and fixed with 4% paraformaldehyde. Cryostat sections were prepared by the standard technique and observed under a fluorescence microscope. The experiment was repeated five times, with the same results each time.
Contraction of Basilar Artery
Time Course of Contraction. Twenty-four hours after the intracisternal injection of antisense oligoDNA, sense oligoDNA, or Tris-EDTA, the BA was exposed and visualized with a surgical microscope equipped with a charge-coupled device (CCD) camera and a video monitor. The BA was then treated with 100 l of hemolysate containing 10 Ϫ3 M oxyhemoglobin, and the diameter of the BA was measured in the same site of the middle portion every 10 minutes. Blood pressure and heart rate were recorded continuously. Ventilation was adjusted as needed to maintain a PaCO 2 level of 35 to 45 mm Hg. The numbers of rats used for antisense oligoDNA, sense oligoDNA, and Tris-EDTA injection were eight, eight, and 10, respectively. During the course of the experiment, no dramatic changes in blood pressure, heart rate, or PaCO 2 were observed.
Time Course of Inhibitory Effects of Antisense OligoDNA on Contraction. At 24, 72, and 96 hours after the intracisternal injection of antisense oligoDNA, sense oligoDNA, or Tris-EDTA, the BA was exposed. The constriction response of the BA to 100 l of hemolysate containing 10 Ϫ3 M oxyhemoglobin was then measured at 30 minutes by monitoring the change in arterial diameter with the CCD camera. The numbers of rats used for these time-course experiments were 12, 11, and 10 for 24, 72, and 96 hours, respectively, after administration of antisense oligoDNA, sense oligoDNA, or Tris-EDTA.
The RNA Assay
We initially ascertained the effect of antisense oligoDNA in suppressing mRNA expression using the reverse transcription-polymerase chain reaction (RT-PCR) assay. Twenty-four hours after the intracisternal injection of 100 l antisense oligoDNA, the BA was exposed by the cervical transclival approach and treated with 100 l of hemolysate (10 Ϫ3 M oxyhemoglobin) for 30 minutes. A part of the BA exposed to the hemolysate was excised, and mRNA was prepared from it by use of an mRNA purification kit. Then RT was performed with oligo-dT primers using a T-primed firststrand kit. The PCR was performed as described. 28 Primers for ET mRNA were 5Ј-GTTGTCCCTGCTCCTCCTTG-3Ј (sense) and 5Ј-GCATGGAGAGCGCAGAGTTG-3Ј (reverse), and primers for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were 5Ј-TGAAGGTCGGTGTCAACGGATTTGGC-3Ј (sense) and 5Ј-CATGTAGGCCATAGGTCCACCAC-3Ј (reverse).
The PCR was programmed with a thermal controller to perform the initial melt at 94˚C for 3 minutes and 30 cycles of the following sequential steps: 94˚C, 1 minute (melt); 60˚C, 1 minute (anneal); 72˚C, 3 minutes (extend); and 72˚C, 7 minutes (final extension). The PCR products were run on 1% agarose gels and blotted onto nylon filters. Southern blot analysis was performed by the standard method. 16 The probe was 32 P-labeled oligoDNA, 5Ј-GAACTC-CGAGCCCAAAGTACC-3Ј, which is from the complementary DNA sequence (nucleotide numbers 385-405 counting from the translation start site) for the rat ppET-1. 25 
Morphological Changes in Arterial Walls
Twenty-four hours after the injection of antisense oligoDNA or sense oligoDNA, the BA was exposed and 100 l of hemolysate was applied to it. Thirty minutes later the animals were killed by perfusion fixation with 4% paraformaldehyde-0.1% glutaraldehyde. The BA was then removed along with the brainstem and immersed overnight in the same fixative at 4˚C and postfixed in 1% osmium tetroxide for 1 hour at 4˚C. Ultrathin sections were cut transversely to the vascular axis with an ultramicrotome and examined by transmission electron microscopy.
Sources of Supplies and Equipment
The MTT was purchased from Sigma Chemical Co., St. Louis, MO. The Microplate Reader spectrophotometer (model MTP120) was manufactured by Corona Electric Co. Ltd., Tokyo, Japan. The QuickPrep Micro mRNA purification and T-Primed FirstStrand kits were purchased from Pharmacia Biotetch Inc., Uppsala, Sweden. The thermocontroller (model PTC-100) was provided by MJ Research, Inc., Boston, MA.
Results
Cytotoxicity of the Phosphorothioate OligoDNA
To determine the concentration of the phosphorothioate oligoDNA for use in in vivo experiments, we examined the cytotoxicity of the antisense oligoDNA and sense oligoDNA by the MTT assay using cultured fibroblasts. 20 This assay uses the tetrazolium ring of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, which is cleaved only by dehydrogenase enzymes in active mitochondria in living cells. Human lung fibroblasts (MRC-9) were incubated with or without phosphorothioate oligo-DNA for 24 hours, and the remaining living cells were assayed using the MTT method. The absorbance from the living cells incubated with Tris-EDTA rather than phosphorothioate oligoDNAs was used as control. As shown in Fig. 1 , we did not detect any significant cytotoxicity of the phosphorothioate oligoDNAs at concentrations of less than 10 M; however, at a concentration of 30 M they had some effect on viability (p Ͻ 0.05). Therefore, we decided to use the concentration of 10 M for further in vivo experiments.
Antisense OligoDNA Uptake by BA
The cerebral vasculature has a special anatomy; lowmolecular-weight agents administered via the CSF are able to enter the blood through arterial walls. To discover where the labeled antisense oligoDNAs are incorporated, we labeled them with fluorescence and traced the materials using fluorescence microscopy. Twenty-four hours after an intracisternal antisense oligoDNA injection, fluorescence-labeled materials were distributed in all layers of the BA wall (Fig. 2) , especially on the endothelial side. This indicates that the antisense oligoDNAs in the cerebral subarachnoid fluid were incorporated into the cells in the arterial wall through the adventitia.
Inhibition of Contraction With Antisense OligoDNA for ppET-1 mRNA
Time Course of Contraction. After we dissolved oligo-DNA in Tris-EDTA, every 10 minutes after hemolysate administration we measured the diameter of the BA treated with Tris-EDTA. As shown in Fig. 3 , the diameter had decreased rapidly to 60% of its original size by 10 minutes, then remained constant at that level for up to 1 hour. This transition of the diameter change has been observed in several experimental vasospasm models. 7, 9, 11 Almost the same transition pattern of the diameter was observed with sense oligoDNA treatment, as also seen in Fig. 3 . Strikingly, the antisense oligoDNA-treated BA showed a different response to hemolysate administration: the first reaction to hemolysate was almost the same (60% of the baseline) as that of Tris-EDTA or sense oligoDNA treatment, but after 10 minutes of hemolysate exposure the artery started recovering. After 50 minutes of hemolysate exposure the diameter returned to 88% of its original size.
The vascular contraction was significantly inhibited by antisense oligoDNA by 20 minutes of hemolysate exposure and thereafter. As was the case for sense oligoDNA or Tris-EDTA treatment, application of saline alone had no significant effect on arterial diameter (data not shown). These data indicate that the lag time needed for ppET-1 to be secreted from cells in the BA in response to the hemolysate was approximately 20 minutes and that ppET-1 is responsible for 88% of the vascular contraction. Blood pressure and PCO 2 in blood did not change much during the study.
Duration of the Effect. To judge how long the inhibitory effect of the antisense oligoDNA injected into the cisterna magna lasts in this model, we injected antisense oligo-DNA, sense oligoDNA, or Tris-EDTA and waited for 24, 72, and 96 hours before measuring the vasoconstrictive response to hemolysate. As shown in Fig. 4 , sense K. Onoda, et al. oligoDNA-or Tris-EDTA-treated artery responded to the hemolysate exposure with a constant diameter that was 72% of the original. However, antisense oligoDNA showed a significant inhibitory effect up to 72 hours after the injection but the inhibitory effect did not last until 96 hours.
Furthermore, it took a long time for the sense oligo-DNA-treated artery to recover after the hemolysate exposure. However, the artery treated with antisense oligo-DNA recovered much faster than that treated with sense oligoDNA (data not shown). This suggests that ppET-1 may play a role as a long-lasting vasoconstrictor.
Inhibition of ET-1 mRNA Expression by Antisense OligoDNA
To find whether the inhibitory effect of antisense oligo-DNA described above was truly associated with blockage of ppET-1 transcription, we measured mRNA by RT-PCR as described in Materials and Methods. We compared the ppET-1 mRNA expression between the BA treated with antisense oligoDNA and that treated with sense oligo-DNA. Intracisternal antisense oligoDNA injection resulted in a marked decrease in ET-1 mRNA expression compared with the control, sense oligoDNA injection (Fig. 5,  lanes 3 and 4) . There was no significant difference in mRNA expression between the two control experiments, that is, those with sense oligoDNA or Tris-EDTA injection (data not shown). Densitometric analysis demonstrat-
Photomicrographs showing antisense oligoDNA uptake by basilar artery (BA). Twenty-four hours after the intracisternal antisense oligoDNA injection, the BA was dissected out and the incorporation of fluorescence-labeled antisense oligoDNA into the wall was examined by fluorescence microscopy. Fluorescein-labeled materials were distributed in all layers of the basilar arterial wall, especially on the endothelial side, suggesting that the antisense oligoDNAs were directly incorporated into the arterial wall from the adventitia via the cerebrospinal fluid. FIG. 3 . Graph depicting inhibition of contraction with antisense oligoDNA (AD) for preproendothelin-1 messenger RNA (timecourse study). The diameter of the basilar artery (BA) in response to hemolysate stimulation was measured 24 hours after AD, sense oligoDNA (SD), or Tris-EDTA (TE) administration into the cisterna magna. The BA had responded to almost the same extent by 10 minutes after hemolysate stimulation in the three different experiments; AD, SD, or TE administration. Note that the inhibitory effect by antisense AD was significant after 20 minutes of hemolysate exposure. There was no meaningful difference between SD and TE. The result suggests that endothelin-1 itself contributes significantly to vascular contraction in the early stage of hemolysate application.
ed that antisense oligoDNA decreased the level of ppET-1 mRNA to 30% of the control value obtained with sense oligoDNA (data not shown). The mRNA for GAPDH did not differ significantly between antisense and sense oligoDNA groups (Fig. 5, lanes 1 and 2) . Thus, the antisense oligoDNA (including an initiation codon) for ppET-1 mRNA suppressed ppET-1 mRNA expression at the transcription step and/or at the splicing step. We excised the arteries after 30 minutes of hemolysate exposure to compare the mRNA amounts. The response of ppET-1 mRNA expression to the hemolysate was immediate, because the inhibitory effects of antisense oligoDNA were obvious at 20 minutes after hemolysate administration to the BA (Fig. 3) .
Morphological Changes in the Arterial Wall
Observation by electron microscopy showed that the intima, a layer of endothelial cells lining the BA's interior surface, was deformed in the sense oligoDNA-injected group (Fig. 6B) . This deformity was associated with a corrugated internal elastic lamina, which was observed to form in the BAs in response to the hemolysate. Morphological changes in the Tris-EDTA-injected group were also the same, which indicated vascular contraction. On the other hand, the endothelial cells of the BA in the antisense oligoDNA-injected group were spindle-shaped and lined the wall compactly in a single layer (Fig. 6A) . No infiltrates of inflammatory cells were found around the area in which antisense oligoDNA had been injected. These morphological observations indicate that the dramatic changes observed in the antisense oligoDNA-injected group were due to the inhibitory effect of this material on vascular contraction induced by hemolysate.
Discussion
Role of ppET-1 in Hemolysate-Induced Vascular Contraction
The results of the present investigation indicate that ppET-1 might play a major role in rat vascular contraction produced by hemolysate exposure and that it is possible to introduce oligoDNA directly via CSF to inhibit the vascular contraction (the early stage of vasospasm) by the antisense method in vivo.
Antisense oligoDNA injection prior to the hemolysate exposure clearly began inhibiting arterial constriction from 20 minutes after hemolysate administration. The inhibiting effect became maximum at 30 or 40 minutes after hemolysate administration and reached a plateau thereafter. This experiment together with ET-1 mRNA analysis indicates two important issues. One is that ppET-1 is produced in early spasms in rats. The other is that it is produced rapidly but not within 10 minutes in response to stimulation by hemolysate, because antisense oligoDNA's inhibitory effect became obvious after 20 minutes of hemolysate exposure, as shown in Fig. 3 . In a report by Clozel and Watanabe, 5 BQ-123, a peptidic ET receptor antagonist, was said to prevent the early cerebral vasospasm after SAH in rats by previous intracisternal injection of the agent. The inhibitory effect started from 30 minutes and was maximal at 60 minutes posthemorrhage. Reverse transcription-polymerease chain reaction was performed, and ppET-1 mRNA was measured by Southern blotting using specific DNA probes. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was measured as a control (lanes 1 and 2) . Intracisternal AD injection provided a marked decrease in ppET-1 mRNA expression in the BA compared with SD injection (lanes 3 and 4) . The AD containing the initiation codon for ppET-1 mRNA suppressed the expression of ppET-1 at the mRNA transcription or splicing level, and the response of ppET-1 mRNA expression to the hemolysate was immediate (see Fig. 3 ).
This result is in good agreement with that of our present report, considering the experimental differences; for instance, hemolysate or whole blood was used to mimic SAH. Complete inhibition of vasospasm by BQ-123 together with our 88% inhibition of spasm by antisense oligoDNA indicate that ppET-1 might play a major role in early spasm in the rat. Incompleteness of the inhibition in our experiment suggests that the remaining 12% of vasoconstriction may be attributed to other factors. Also, the inhibitory effect of antisense oligoDNA on ppET-1 mRNA was not complete using our technique, indicating the need for improvement.
On the other hand, in cerebral vasospasm models of other species, the ppET-1 showed some increase in protein level. 12, 32 However, the increased level of ppET-1 was not extraordinary, at only 1.7 to approximately 2.2 times above the normal level. This suggests that ppET-1 could act solely as a trigger in the early stage of vasospasm or that its biological constriction effect is not proportional to the amount of protein itself.
This study is the first attempt to introduce antisense oligoDNA into cerebral vessels via the adventitial approach mediated through the CSF. On the other hand, there are other methods, for instance the intraluminal approach using the double-balloon system. Administration of DNA directly into the blood has been tried by different research groups: pig coronal artery, 21 pig femoral artery, 23 dog femoral artery, 15 and rat carotid artery. 4, 18, 19 Incorporation into cells was improved by the method using hemagglutinating virus of Japan liposomes. 19 Intravascular oligoDNA would be a target of degradation by many nonspecific nucleases present in the blood; therefore, a high concentration of oligoDNAs would be required to predict good incorporation into cells. Furthermore, it is dangerous to change the rate of blood flow in cases in which the brain metabolic rate is quite low after SAH.
On the other hand, intraventricular administration of oligoDNA has some advantages. Nuclease activity in rat CSF is known to be relatively low. Also, phosphorothioate oligoDNAs have been shown to be resistant to degradation in the CSF. 31 This novel intracisternal administration of oligoDNAs into the CSF appears hopeful as a first trial. As shown in Fig. 2 , fluorescein isothiocyanate-labeled oligoDNAs injected in the cisterna magna were incorporated into the whole layers of the vascular wall after 24 hours. We believe that this intracisternal approach could be applied for drug delivery to the cerebral vasculature; however, we need further research to improve drug delivery to vascular walls, because cerebral vessels are usually covered by a clot when the intracisternal injection of antisense oligoDNA is attempted after SAH.
It is important to keep the administered oligoDNAs intact and undegraded for a certain time. In a trial of oligo-DNA administration from vascular walls by means of pluronic gel, the oligoDNAs were kept intact and their activity lasted for 1 to 8 weeks. 1, 4, 8, 29 Our experimental system did not show such a long duration of biological effects; the inhibitory effect against vasospasm only lasted for 3 days (Fig. 4) . The difference could be due to the concentration of administered antisense oligoDNA, application of pluronic gel, or other factors. In any event, we believe that this antisense oligoDNA approach could be applied to transient pathogenic changes such as vasospasm after SAH.
In summary, antisense oligoDNA is a powerful new tool for the inhibition of vascular contraction in the rat model of early spasm. Furthermore, we speculate that continued development of the antisense method will facilitate the use of antisense technology to characterize the biological role of gene products activated during vasospasm further and to provide additional therapeutic agents for use in humans. FIG. 6 . Photomicrographs depicting morphological changes in the arterial wall. Twenty-four hours after antisense oligoDNA (AD) or sense oligoDNA (SD) injection, the basilar artery (BA) was observed by electron microscopy. Left: Endothelial cells of the BA from an AD-injected animal were spindle-shaped and lined the lumen smoothly in a single layer. Right: Endothelial cells of the BA from a rat injected with SD were deformed along the corrugated internal elastic lamina, a structural change caused by hemolysate stimulation. Contraction did not take place in the BA with AD administration. Bar = 1 m.
